Pasteur Merieux Connaught Presents Strategy, Forecasts

9 December 1996

Wholly-owned Rhone-Poulenc subsidiary Pasteur Merieux Connaught, a world leader in vaccine development and production, presented its new strategy and corporate image, with a single name for all its affiliates, in Paris, France, last week.

Chairman and chief executive Jean-Jacques Bertrand said that since 1993, PMC has seen important changes - concentrating on vaccines activity, and its partnership with Merck & Co - which require the drawing up of a new strategy based on:

- strengthening the innovation potential to optimize existing vaccines and develop new ones for extending vaccination coverage throughout the world;

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight